Crossmark

The efficacy and safety of pembrolizumab and dostarlimab in advanced endometrial carcinoma: a systematic review

Published Online: 2024-09-10

Authors

Kokori, Emmanuel

Olatunji, Gbolahan

Abdulbasit, Muili

Aderinto, Nicholas
License Information

Text and Data Mining valid from 2024-09-10

Version of Record valid from 2024-09-10
More Information

Article History

Received: 12 March 2024

Accepted: 3 September 2024

First Online: 10 September 2024

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current